Treatment for Metastatic Breast Cancer

Phase-Based Progress Estimates
3
Effectiveness
3
Safety
Metastatic Breast Cancer
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will assess the long-term safety of ribociclib when used in combination with other drugs in participants who have already benefited from the treatment.

Eligible Conditions
  • Metastatic Breast Cancer

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: Up to 5 years

Year 5
Percentage of participants with treatment-emergent adverse events (AES)
Up to 5 years
Clinical benefit rate

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

0 Treatment Group

137 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · Phase 4

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 5 years

Who is running the clinical trial?

Novartis PharmaceuticalsLead Sponsor
2,718 Previous Clinical Trials
3,525,250 Total Patients Enrolled
27 Trials studying Metastatic Breast Cancer
11,854 Patients Enrolled for Metastatic Breast Cancer

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: